

Serial No.: 09/292,411
Group Art Unit: 1632

RECEIVED

AUG 28 2000

TECH CENTER 1600/2900

-- 33. An isolated polypeptide fragment comprising at least 30 consecutive amino acids of SEQ ID NO:2.

-- 34. The isolated polypeptide fragment of claim 35, wherein the isolated polypeptide fragment comprises a heterologous amino acid sequence fused to the at least 30 consecutive amino acids of SEQ ID NO:2.

Remarks

This Response & Amendment is responsive to the Office Communication mailed May 15, 2000 (Paper No. 2). Entry of this Response & Amendment are respectfully requested.

Claims

Claims 11-24 were pending. Claims 11-24 were subject to an eleven (11) way Restriction Requirement.

Claims 21-24 have been canceled without prejudice or disclaimer of the subject matter therein. Moreover, Applicants reserve the right to prosecute, in one or more patent applications, the canceled claims, the claims to non-elected inventions, the claims as originally filed, and any other claims supported by the specification.

New claims 25-34 have been added.

It is believed that entry of this Amendment will not require payment of any additional claim fees. Notwithstanding, Applicants hereby authorize the Commissioner to charge any additional claim fees required by entry of this Amendment to Deposit Account No. 50-0258.

Support

Support for the new claims is either apparent or is as described in the text below. Specifically, support for polypeptides fragments comprising at least 30/50 consecutive amino acids of SEQ ID NO:2 may be found in the specification at, for example, page 20, lines 26-32. Support for "an acceptable carrier" may be found in the specification at, for example, page 46, lines 9-16. Support for "fusion polypeptide" may be found in the specification at, for example,

Serial No.: 09/292,411
Group Art Unit: 1632

RECEIVED

AUG 28 2000

TECH CENTER 1600/2900

page 15, line 27 through page 16, line 2; page 18, lines 17-26; and page 21, lines 14-23. No new matter is added.

Election/Restriction

Applicants hereby elect to prosecute Group I (claims 12-13), without traverse. While the election of Group I is without traverse, Applicants reserve the right to traverse restriction requirements between the other asserted claim groups.

Closing Remarks

Entry of the Response & Amendment and allowance of the pending claims are respectfully requested.


FEE DEFICIENCY

- ☒ If any additional extension is required, please consider this paper to comprise a petition for such an extension of time; Any fee for any extension required for consideration of this paper but not enumerated above can be charged to Account No. 50-0258.

AND/OR

- ☒ If any additional fee is required for consideration of this paper, please charge Account No. 50-0258.

Respectfully submitted,



Thomas S. Deibert
Registration No. 40,984
Allen Bloom
Registration No. 29,135
Attorney for Applicants

DECHERT PRICE & RHOADS
Princeton Pike Corporate Center
PO Box 5218
Princeton, New Jersey 08543-5218
Fax: (609) 620-3259
Attn: Thomas S. Deibert, Esq.
(609) 620-3231